The costs and timelines for production are tied to the complexity of the chemistry and the resources necessary for manufacturing. When advancing an asset by developing the initial chemical synthesis into a scalable process, the arguably biggest impact on reducing costs, complexity, and overall lab operations is driven by knowing the solubility landscape. The earlier the solubility landscape of an asset can be evaluated, the less risk there is of becoming locked into a process that can no longer be easily changed. While the time and cost savings for an efficient process are substantial and well-documented, we commonly hear that this critical stage in process development is overlooked for two main reasons: (1) time pressure to prepare material and (2) lack of resources for generating data.
At the preclinical stage when multiple teams are trying to prioritize the use of available milligrams of material, the only viable option to making informed decisions is doing more with less, without sacrificing quality.
The Solubility Company’s SPA® platform is the ideal solution for any drug developer ready to generate a data package to guide process development. The (literally) microscopic sample quantities enable you to generate comprehensive knowledge very early and avoid downstream time pressures; the IP of your early assets stays safe, as there is no need to reveal chemical structures; and outsourcing is streamlined to address any internal resource limitations – talk to our experts.
Our Quakertown, PA and Helsinki, Finland laboratories have streamlined sample submission processes, shaving further time off the already impressive data turn around of The Solubility Company’s SPA® Platform.
If you’re looking to Research Smart and Deliver Early, click here to drop us a message!
Viikinkaari 4
00790 Helsinki
FINLAND
1 Broadway
Cambridge MA 01242
United States
Workshop: Mitigating Risk in Small Molecule Drug Development
6 February 2025, MassBioHub, Cambridge, MA